TODD JASON BRODER
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
- Where
- ST AUGUSTINE, FL
- NPI
- 1699849349
- Received
- $1,588,617 in 2,341 records, 2019 to 2025
- As principal investigator
- $103,998 of research payments to others in 36 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 478 | $422,654 |
| 2024 | General payment | 565 | $419,230 |
| 2023 | General payment | 434 | $324,663 |
| 2022 | General payment | 366 | $202,286 |
| 2021 | General payment | 125 | $68,206 |
| 2020 | General payment | 117 | $48,895 |
| 2019 | General payment | 256 | $102,681 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 721 | $396,511 | 2019–2025 |
| Janssen Pharmaceuticals, Inc | 590 | $395,823 | 2019–2025 |
| Axsome Therapeutics, Inc. | 443 | $341,913 | 2023–2025 |
| ABBVIE INC. | 259 | $216,754 | 2021–2025 |
| E.R. Squibb & Sons, L.L.C. | 139 | $123,764 | 2024–2025 |
| Alkermes, Inc. | 107 | $61,626 | 2019–2025 |
| H. Lundbeck A S | 22 | $46,277 | 2024–2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $2,438 | 2020–2025 |
| Neuronetics, Inc. | 5 | $1,376 | 2019–2021 |
| LivaNova USA, Inc. | 11 | $683 | 2021–2022 |
| Neurocrine BioSciences, Inc. | 10 | $501 | 2022–2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $450 | 2020–2025 |
| Vanda Pharmaceuticals Inc. | 1 | $105 | 2024 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $100 | 2023 |
| Teva Pharmaceuticals USA, Inc. | 4 | $96 | 2023–2024 |
| Allergan, Inc. | 1 | $81 | 2019 |
| Lundbeck LLC | 2 | $53 | 2024 |
| Sage Therapeutics, LLC | 1 | $34 | 2024 |
| Indivior Inc. | 1 | $23 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 400 | $969,677 |
| Travel and Lodging | 916 | $216,341 |
| Consulting Fee | 80 | $209,410 |
| Honoraria | 36 | $147,067 |
| Food and Beverage | 905 | $46,054 |
| Education | 4 | $65 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | ABBVIE INC. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-18 | ABBVIE INC. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-15 | E.R. Squibb & Sons, L.L.C. | $173 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-11 | ABBVIE INC. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-11 | E.R. Squibb & Sons, L.L.C. | $2,104 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-10 | Neurocrine BioSciences, Inc. | $124 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-10 | ABBVIE INC. | $57 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-10 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-09 | ABBVIE INC. | $57 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-09 | ABBVIE INC. | $32 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-04 | E.R. Squibb & Sons, L.L.C. | $4,209 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-04 | ABBVIE INC. | $3,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-25 | Janssen Pharmaceuticals, Inc | $182 | Travel and Lodging | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-11-24 | Janssen Pharmaceuticals, Inc | $4,145 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-11-21 | E.R. Squibb & Sons, L.L.C. | $129 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-21 | Axsome Therapeutics, Inc. | $125 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-11-21 | ABBVIE INC. | $59 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-20 | ABBVIE INC. | $3,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-20 | ABBVIE INC. | $114 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-20 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-20 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-19 | Janssen Pharmaceuticals, Inc | $115 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-11-18 | ABBVIE INC. | $60 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-18 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-14 | ABBVIE INC. | $128 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-14 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-13 | ABBVIE INC. | $3,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-13 | E.R. Squibb & Sons, L.L.C. | $146 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-12 | Janssen Pharmaceuticals, Inc | $1,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-11-12 | E.R. Squibb & Sons, L.L.C. | $333 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-10 | E.R. Squibb & Sons, L.L.C. | $283 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-10 | E.R. Squibb & Sons, L.L.C. | $45 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-07 | Alkermes, Inc. | $18 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-11-06 | ABBVIE INC. | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-11-05 | Otsuka America Pharmaceutical, Inc. | $3,078 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-11-05 | Otsuka America Pharmaceutical, Inc. | $267 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-11-05 | Otsuka America Pharmaceutical, Inc. | $44 | Food and Beverage | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-11-05 | Otsuka America Pharmaceutical, Inc. | $17 | Food and Beverage | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-11-04 | E.R. Squibb & Sons, L.L.C. | $2,404 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-29 | H. Lundbeck A S | $3,200 | Honoraria | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-10-29 | H. Lundbeck A S | $600 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-10-29 | H. Lundbeck A S | $115 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-10-27 | ABBVIE INC. | $147 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-27 | ABBVIE INC. | $37 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-16 | ABBVIE INC. | $3,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-16 | ABBVIE INC. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-16 | ABBVIE INC. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $578 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $326 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $134 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $64 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $51 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $49 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $29 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $29 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | $29 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-02 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-02 | ABBVIE INC. | $82 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-02 | ABBVIE INC. | $5 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-01 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-30 | ABBVIE INC. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-30 | ABBVIE INC. | $196 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-30 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-30 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-30 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-29 | ABBVIE INC. | $44 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-25 | ABBVIE INC. | $3,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-23 | E.R. Squibb & Sons, L.L.C. | $1,563 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-22 | Janssen Pharmaceuticals, Inc | $1,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-09-18 | E.R. Squibb & Sons, L.L.C. | $173 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-18 | E.R. Squibb & Sons, L.L.C. | $46 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-18 | E.R. Squibb & Sons, L.L.C. | $45 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-18 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-18 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-17 | E.R. Squibb & Sons, L.L.C. | $2,044 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-17 | ABBVIE INC. | $315 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-17 | ABBVIE INC. | $305 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-17 | ABBVIE INC. | $118 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-17 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-15 | E.R. Squibb & Sons, L.L.C. | $4,810 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-10 | Alkermes, Inc. | $96 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-09-08 | ABBVIE INC. | $5,500 | Consulting Fee | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-08 | E.R. Squibb & Sons, L.L.C. | $5,171 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-08 | E.R. Squibb & Sons, L.L.C. | $1,804 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-08 | ABBVIE INC. | $72 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-08 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-02 | E.R. Squibb & Sons, L.L.C. | $1,803 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-02 | E.R. Squibb & Sons, L.L.C. | $556 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-02 | E.R. Squibb & Sons, L.L.C. | $407 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-02 | E.R. Squibb & Sons, L.L.C. | $97 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-02 | E.R. Squibb & Sons, L.L.C. | $26 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-02 | E.R. Squibb & Sons, L.L.C. | $22 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-08-25 | ABBVIE INC. | $1,925 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-08-21 | E.R. Squibb & Sons, L.L.C. | $446 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-08-21 | E.R. Squibb & Sons, L.L.C. | $219 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-08-21 | E.R. Squibb & Sons, L.L.C. | $120 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-08-19 | H. Lundbeck A S | $11,268 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-08-19 | H. Lundbeck A S | $2,600 | Honoraria | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-08-19 | E.R. Squibb & Sons, L.L.C. | $2,103 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-19 | H. Lundbeck A S | $614 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-08-19 | H. Lundbeck A S | $283 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-08-19 | H. Lundbeck A S | $162 | Food and Beverage | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-08-19 | H. Lundbeck A S | $84 | Food and Beverage | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-08-15 | Axsome Therapeutics, Inc. | $9,450 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-08-15 | Axsome Therapeutics, Inc. | $9,450 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-08-14 | E.R. Squibb & Sons, L.L.C. | $55 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-08-12 | E.R. Squibb & Sons, L.L.C. | $4,209 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-08-09 | ABBVIE INC. | $469 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-08-08 | ABBVIE INC. | $67 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-08-08 | ABBVIE INC. | $47 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-08-08 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-08-04 | Axsome Therapeutics, Inc. | $31 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-30 | E.R. Squibb & Sons, L.L.C. | $75 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-07-25 | Axsome Therapeutics, Inc. | $407 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-25 | Axsome Therapeutics, Inc. | $407 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-25 | Axsome Therapeutics, Inc. | $150 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-25 | Axsome Therapeutics, Inc. | $150 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-25 | Axsome Therapeutics, Inc. | $113 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-25 | Axsome Therapeutics, Inc. | $113 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-23 | E.R. Squibb & Sons, L.L.C. | $121 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-07-21 | Otsuka America Pharmaceutical, Inc. | $25 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-07-16 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $121 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-07-09 | E.R. Squibb & Sons, L.L.C. | $3,608 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-07-08 | Axsome Therapeutics, Inc. | $6,413 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-08 | Axsome Therapeutics, Inc. | $5,738 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-08 | Axsome Therapeutics, Inc. | $476 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-08 | Axsome Therapeutics, Inc. | $374 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-08 | Axsome Therapeutics, Inc. | $173 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-08 | Axsome Therapeutics, Inc. | $120 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-08 | Axsome Therapeutics, Inc. | $64 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-08 | Axsome Therapeutics, Inc. | $56 | Food and Beverage | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-08 | Axsome Therapeutics, Inc. | $45 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-08 | Axsome Therapeutics, Inc. | $40 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-08 | Axsome Therapeutics, Inc. | $23 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-07-08 | Axsome Therapeutics, Inc. | $8 | Food and Beverage | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-27 | Axsome Therapeutics, Inc. | $85 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-26 | Axsome Therapeutics, Inc. | $5,738 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-26 | Axsome Therapeutics, Inc. | $461 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-26 | Axsome Therapeutics, Inc. | $437 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-26 | Axsome Therapeutics, Inc. | $142 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-26 | Axsome Therapeutics, Inc. | $118 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-26 | Axsome Therapeutics, Inc. | $86 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-26 | Axsome Therapeutics, Inc. | $48 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-26 | Axsome Therapeutics, Inc. | $41 | Food and Beverage | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-26 | Axsome Therapeutics, Inc. | $17 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-25 | Axsome Therapeutics, Inc. | $3,375 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-25 | Axsome Therapeutics, Inc. | $3,038 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-25 | Otsuka America Pharmaceutical, Inc. | $877 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-25 | Axsome Therapeutics, Inc. | $215 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-25 | Axsome Therapeutics, Inc. | $113 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-25 | Axsome Therapeutics, Inc. | $73 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-25 | Axsome Therapeutics, Inc. | $24 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-25 | Axsome Therapeutics, Inc. | $5 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-24 | Axsome Therapeutics, Inc. | $4,725 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-24 | Axsome Therapeutics, Inc. | $4,388 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-24 | Axsome Therapeutics, Inc. | $353 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-24 | Axsome Therapeutics, Inc. | $198 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-24 | Axsome Therapeutics, Inc. | $121 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-24 | Axsome Therapeutics, Inc. | $86 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-24 | Axsome Therapeutics, Inc. | $41 | Food and Beverage | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-24 | Axsome Therapeutics, Inc. | $10 | Travel and Lodging | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-19 | E.R. Squibb & Sons, L.L.C. | $101 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-06-18 | Otsuka America Pharmaceutical, Inc. | $112 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-18 | Otsuka America Pharmaceutical, Inc. | $86 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-18 | Otsuka America Pharmaceutical, Inc. | $72 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-18 | Otsuka America Pharmaceutical, Inc. | $17 | Food and Beverage | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-18 | Otsuka America Pharmaceutical, Inc. | $11 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-18 | Otsuka America Pharmaceutical, Inc. | $10 | Food and Beverage | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-16 | E.R. Squibb & Sons, L.L.C. | $2,104 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-06-14 | Otsuka America Pharmaceutical, Inc. | $112 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-14 | Otsuka America Pharmaceutical, Inc. | $86 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-14 | Otsuka America Pharmaceutical, Inc. | $25 | Food and Beverage | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-14 | Otsuka America Pharmaceutical, Inc. | $5 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-10 | E.R. Squibb & Sons, L.L.C. | $2,104 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-06-06 | Otsuka America Pharmaceutical, Inc. | $3,564 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-06 | Otsuka America Pharmaceutical, Inc. | $3,564 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-05 | Otsuka America Pharmaceutical, Inc. | $665 | Travel and Lodging | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-06-05 | Otsuka America Pharmaceutical, Inc. | $108 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-06-04 | Otsuka America Pharmaceutical, Inc. | $390 | Travel and Lodging | In-kind items and services | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-04 | Otsuka America Pharmaceutical, Inc. | $97 | Food and Beverage | In-kind items and services | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-04 | Otsuka America Pharmaceutical, Inc. | $26 | Travel and Lodging | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-03 | Otsuka America Pharmaceutical, Inc. | $390 | Travel and Lodging | In-kind items and services | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-06-03 | Otsuka America Pharmaceutical, Inc. | $121 | Food and Beverage | In-kind items and services | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-05-30 | Axsome Therapeutics, Inc. | $588 | Travel and Lodging | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-05-29 | Janssen Pharmaceuticals, Inc | $1,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-05-29 | Axsome Therapeutics, Inc. | $128 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-05-28 | Neurocrine BioSciences, Inc. | $140 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-28 | ABBVIE INC. | $48 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-05-28 | E.R. Squibb & Sons, L.L.C. | $33 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-05-23 | Otsuka America Pharmaceutical, Inc. | $3,078 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-05-19 | Janssen Pharmaceuticals, Inc | $1,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-05-16 | ABBVIE INC. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-05-16 | Janssen Pharmaceuticals, Inc | $1,220 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-05-15 | Otsuka America Pharmaceutical, Inc. | $121 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-05-12 | Axsome Therapeutics, Inc. | $1,350 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-05-09 | Otsuka America Pharmaceutical, Inc. | $351 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-05-08 | Janssen Pharmaceuticals, Inc | $4,145 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-05-07 | Axsome Therapeutics, Inc. | $5,738 | Honoraria | Cash or cash equivalent | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-05-07 | E.R. Squibb & Sons, L.L.C. | $2,405 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-05-07 | E.R. Squibb & Sons, L.L.C. | $1,866 | Travel and Lodging | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 |
The latest 200 records of 2,341.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-06-17 | LivaNova USA, Inc. | Advarra, Inc. (Central IRB) | $90 | RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of | 2025 |
| 2024-11-19 | LivaNova USA, Inc. | Advarra, Inc. (Central IRB) | $300 | RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of | 2024 |
| 2024-11-19 | LivaNova USA, Inc. | Advarra, Inc. (Central IRB) | $85 | RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of | 2024 |
| 2024-10-22 | LivaNova USA, Inc. | Advarra, Inc. (Central IRB) | $85 | RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of | 2024 |
| 2024-10-03 | LivaNova USA, Inc. | Advarra, Inc. (Central IRB) | $85 | RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of | 2024 |
| 2024-07-30 | LivaNova USA, Inc. | Advarra, Inc. (Central IRB) | $1,280 | RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of | 2024 |
| 2024-07-23 | LivaNova USA, Inc. | Advarra, Inc. (Central IRB) | $820 | RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of | 2024 |
| 2024-05-08 | Neurocrine BioSciences, Inc. | FLORIDA CENTER FOR TMS LLC | $2,051 | A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported | 2024 |
| 2024-03-12 | LivaNova USA, Inc. | Advarra, Inc. (Central IRB) | $3,340 | RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of | 2024 |
| 2024-03-12 | LivaNova USA, Inc. | Advarra, Inc. (Central IRB) | $3,340 | RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of | 2024 |
| 2024-03-08 | Neurocrine BioSciences, Inc. | FLORIDA CENTER FOR TMS LLC | $2,051 | A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported | 2024 |
| 2024-02-20 | LivaNova USA, Inc. | Advarra, Inc. (Central IRB) | $85 | RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of | 2024 |
| 2024-02-20 | LivaNova USA, Inc. | Advarra, Inc. (Central IRB) | $85 | RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of | 2024 |
| 2024-02-16 | Neurocrine BioSciences, Inc. | FLORIDA CENTER FOR TMS LLC | $1,795 | A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported | 2024 |
| 2023-12-27 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $1,638 | RECOVER | 2023 |
| 2023-12-27 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $132 | RECOVER | 2023 |
| 2023-09-06 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $3,408 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2023 |
| 2023-08-01 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $5,178 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2023 |
| 2023-07-18 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $132 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2023 |
| 2023-07-11 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $3,540 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2023 |
| 2023-05-16 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $4,782 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2023 |
| 2023-04-26 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $3,276 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2023 |
| 2023-04-18 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $3,204 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2023 |
| 2023-04-13 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $20,826 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2023 |
| 2023-01-25 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $12,882 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2023 |
| 2022-12-01 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $3,144 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-11-22 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $1,638 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-10-26 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $5,046 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-09-09 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $162 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-09-07 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $13,776 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-07-27 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $702 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-07-21 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $204 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-06-30 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $366 | The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment meas | 2022 |
| 2022-06-23 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $432 | The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment meas | 2022 |
| 2022-06-16 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $408 | The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment meas | 2022 |
| 2022-06-09 | LivaNova USA, Inc. | FLORIDA CENTER FOR TMS | $3,630 | The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment meas | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In St. Augustine, FL, county St. Johns County, FL, state Florida; placed by its city name.
| Measure | Place (city or town) St. Augustine, FL | County St. Johns County, FL | State Florida |
|---|---|---|---|
| Population B01003 | 15,351 | 306,934 | 22,416,077 |
| Population, 2020 census P1 | 14,329 | 273,425 | 21,538,187 |
| Median age B01002 | 49.9 | 44.2 | 42.6 |
| Under 18 B01001 | 8.4% | 21.6% | 19.5% |
| 65 and over B01001 | 27.4% | 21.1% | 21.3% |
| Households B11001 | 6,529 | 115,794 | 8,752,810 |
| Foreign born B05002 | 7.0% | 9.4% | 21.9% |
| Median household income B19013 | $78,151 | $109,839 | $74,568 |
| Median family income B19113 | $107,353 | $134,118 | $89,891 |
| Per capita income B19301 | $47,204 | $57,346 | $42,609 |
| Poverty rate B17001 | 14.1% | 6.5% | 12.6% |
| Unemployment rate B23025 | 3.8% | 3.3% | 4.8% |
| Civilian labor force B23025 | 7,862 | 149,958 | 11,016,578 |
| Mean commute (minutes) B08013 | 20.1 | 26.9 | 28.0 |
| Bachelor's degree or higher B15003 | 44.6% | 50.9% | 34.1% |
| Housing units B25001 | 8,715 | 133,504 | 10,256,470 |
| Owner-occupied B25003 | 63.0% | 82.2% | 67.6% |
| Renters B25003 | 37.0% | 17.8% | 32.4% |
| Median home value B25077 | $439,800 | $489,200 | $359,000 |
| Median gross rent B25064 | $1,653 | $1,922 | $1,669 |
| White, not Hispanic B03002 | 84.1% | 77.4% | 50.4% |
| Black B03002 | 3.4% | 4.9% | 14.6% |
| Hispanic or Latino B03002 | 6.8% | 9.1% | 27.4% |
| Asian B03002 | 1.9% | 3.7% | 2.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.0% | 0.1% |
Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in St. Augustine, FL.
Comments